The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2023 | The current role of chemotherapy in the treatment of Hodgkin lymphoma & the impact of novel agents
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, shares some insights into the current role of chemotherapy in the treatment of Hodgkin lymphoma (HL) and how this is changing with the introduction of novel agents, including brentuximab vedotin, nivolumab and pembrolizumab. Dr Sureda also highlights the possibility of moving towards chemotherapy-free regimens in the future. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
